Systemic sclerosis-associated pulmonary arterial hypertension (SSc-PAH) carries a poor prognosis, and treatment decisions are often complicated by coexisting left-heart disease, lung disease, chronic thromboembolic disease, or pulmonary veno-occlusive disease-like vasculopathy. The role of sotatercept as part of initia...
Yuichi Tamura, Sarasa Isobe, Hiroyuki Fujii et al.· Frontiers in Cardiovascular...· 0 citations
OBJECTIVES
To characterize clinical manifestations, major organ involvement, real-world treatment patterns, and factors associated with severity classification in Japanese patients with mixed connective tissue disease (MCTD), aiming to clarify its heterogeneous clinical spectrum.
METHODS
This nationwide retrospective...
S. Kubo, Yurie Kanda, Hideto Kameda et al.· Rheumatology· 0 citations
Systemic sclerosis (SSc) is a multifaceted systemic autoimmune disease, characterised by the interplay of vascular alterations, immune dysregulation, and fibrosis. The molecular changes and the clinical presentation of SSc are highly heterogeneous and vary considerably between individual patients. This heterogeneity ha...
Jörg H. W. Distler, S. Assassi, A. Gabrielli et al.· Annals of the Rheumatic Dise...· 0 citations
To investigate the demographic and clinical features of systemic sclerosis (SSc) patients with anti-U1RNP antibodies using the European Scleroderma Trials and Research (EUSTAR) database, a phenotype less well-defined in SSc than other more commonly associated antibodies.
SSc patients fulfilling classificat...
Wan-Long Wu, M. Venables, E. Hachulla et al.· Arthritis Research & The...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.